PlainPharmaWatch

CMS Open Payments · Program Year 2024

GC Biopharma USA, Inc.

GC Biopharma USA, Inc. reported $8,133.61 across General Payments, Research, and Ownership to 158 physicians and teaching hospitals across 158 transactions.

See the rankings → How this is sourced
$8.1K
All-tracks total
158
Transactions
158
Recipients
#1661
of 1,925 companies

GC Biopharma USA, Inc. reported $8,133.61 across all CMS Open Payments tracks (General + Research + Ownership) to 158 physicians and teaching hospitals in Program Year 2024 - ranking #1661 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $8,133.61, averaging $51.48 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer gc-biopharma-usa-inc GC Biopharma USA, Inc.

$8.1K · #1661/1,925 · 0.0% industry · PY2024

  • TOT $8.1K
  • RANK #1661
  • SHARE 0.0%
  • TXN 158
  • RCP 158
  • CAT 1
  • GEN $8.1K
  • TOP1 61.5%
  • PY 2024

Volume peers

Nearest volume peer: Nipro Medical Corporation ($8.2K)

Darco International, Inc.$8.5KNeuraSignal Inc.$8.3KNipro Medical Corporation$8.2KGC Biopharma USA, Inc. (this)$8.1KOWP Pharmaceuticals, Inc.$7.8K
All-tracks payment totals near GC Biopharma USA, Inc. (CMS Open Payments PY2024)

GC Biopharma USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for GC Biopharma USA, Inc.

In Program Year 2024, GC Biopharma USA, Inc. reported $8,133.61 in payments to 158 physicians and teaching hospitals across 158 individual transactions, an average of $51.48 per transaction and $51.48 per recipient. That total places GC Biopharma USA, Inc. at rank #1661 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Food and Beverage" leads the 1-category general-payment breakdown below at $8.1K (100.0% of General Payments, 158 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

GC Biopharma USA, Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $8.1K, 100.0% of General Payments.

How GC Biopharma USA, Inc. divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$8.1K
Payment Type Amount Transactions
Food and Beverage $8.1K 158

Recipient Concentration in General Payments

The five largest recipient relationships account for $5,187.66 (63.8%) of $8,133.61 in this company's General Payments records across 141 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for GC Biopharma USA, Inc.

The five named recipients with the highest reported General Payments from this company

Raffi Tachdjian$5.0KTodd Hrabak$57.85Michael Polcari$45.22Duane Wong$42.78Ryan CASPER$41.81
  1. 1

    Raffi Tachdjian

    $5,000.00 across 1 reported transactions

  2. 2

    Todd Hrabak

    $57.85 across 3 reported transactions

  3. 3

    Michael Polcari

    $45.22 across 2 reported transactions

  4. 4

    Duane Wong

    $42.78 across 3 reported transactions

  5. 5

    Ryan CASPER

    $41.81 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as GC Biopharma USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about GC Biopharma USA, Inc..

Withings, Inc.

HHI 3792

Voximetry, Inc.

HHI 3788

Mercator MedSystems, Inc.

HHI 3799

Corbin Clinical Resources

HHI 3778

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with GC Biopharma USA, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download GC Biopharma USA, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.